Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy

We evaluated the efficacy and safety of tacrolimus (TAC) combined with corticosteroids in treating patients with idiopathic membranous nephropathy (IMN). One hundred seventy-seven biopsy-proven IMN patients were recruited in this retrospective clinical study. Sixty patients received TAC (target bloo...

Full description

Bibliographic Details
Main Authors:	W. Cui, X. Lu, X. Min, M. Liu, S. Guan, Y. Wang, M. Luo, W. Li, Q. Li, W. Dong, L. Miao, P. Luo
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Cyclophosphamide Efficacy Idiopathic membranous nephropathy Retrospective clinical study Tacrolimus
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000400703&lng=en&tlng=en

Similar Items

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
by: Honghong Zou, et al.
Published: (2019-01-01)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
by: Haiting Huang, et al.
Published: (2021-01-01)

Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy
by: Lei Peng, et al.
Published: (2016-01-01)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
by: Raja Ramachandran, et al.
Published: (2017-07-01)

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy
by: Lina Shao, et al.
Published: (2019-10-01)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
by: Shun-Lai Shang, et al.
Published: (2018-07-01)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
by: Lin S, et al.
Published: (2019-07-01)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
by: Lin W, et al.
Published: (2019-07-01)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
by: Shasha Chen, et al.
Published: (2020-02-01)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
by: Zhang C, et al.
Published: (2020-04-01)

Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis
by: Jiatong Li, et al.
Published: (2019-12-01)

Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature
by: Yuejuan Pan, et al.
Published: (2020-12-01)

Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy
by: XIE Xinfu, et al.
Published: (2021-06-01)

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
by: Wenkai Guo, et al.
Published: (2020-02-01)

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
by: Aikaterini Nikolopoulou, et al.
Published: (2019-09-01)

Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study
by: Jia Wang, et al.
Published: (2017-07-01)

Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013-09-01)

Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: A prospective study
by: N Prasad, et al.
Published: (2018-01-01)

Membranous nephropathy: Treatment outline and risk stratification
by: Ziad Arabi
Published: (2012-07-01)

Efficacy and safety of tacrolimus‐based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study
by: Xiao‐Juan Zhang, et al.
Published: (2019-10-01)

Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study
by: Zhenbin Jiang, et al.
Published: (2021-04-01)

The elevated levels of urinary angiotensinogen are correlated with the severity of idiopathic membranous nephropathy
by: Ziyong Tang, et al.
Published: (2018-12-01)

A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection
by: Eric M. Yoshida, M.D., M.H.Sc., FR.C.P.C., et al.
Published: (2013-03-01)

Meta‐Analysis of the Diagnostic Efficiency of THSD7A‐AB for the Diagnosis of Idiopathic Membranous Nephropathy
by: Yipeng Liu, et al.
Published: (2020-11-01)

Factors affecting the long-term outcomes of idiopathic membranous nephropathy
by: Hyuk Huh, et al.
Published: (2017-03-01)

Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy
by: Xinxin Chen, et al.
Published: (2019-01-01)

Helper T Cells in Idiopathic Membranous Nephropathy
by: Qihan Zhao, et al.
Published: (2021-05-01)

The impact of coexisting diabetes mellitus on clinical outcomes in patients with idiopathic membranous nephropathy: a retrospective observational study
by: Zhiyong Xie, et al.
Published: (2020-06-01)

How Does Herbal Medicine Treat Idiopathic Membranous Nephropathy?
by: Zhendong Feng, et al.
Published: (2020-07-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)
by: Jean-Marc Naccache, et al.
Published: (2019-04-01)

Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis
by: Peng Y, et al.
Published: (2021-07-01)

The role of adiponectin and its receptor in patients with idiopathic membranous nephropathy complicated with hyperuricemia
by: Liu Tong, et al.
Published: (2021-01-01)

Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients
by: Emrah Günay
Published: (2020-09-01)

Herbal Medicine “Shulifenxiao” Formula for Nephrotic Syndrome of Refractory Idiopathic Membranous Nephropathy
by: Hailan Cui, et al.
Published: (2021-05-01)

Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study
by: Shimojima Yasuhiro, et al.
Published: (2012-11-01)

Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan
by: Makoto Yamaguchi, et al.
Published: (2018-10-01)

Differential expression study of circular RNAs in exosomes from serum and urine in patients with idiopathic membranous nephropathy
by: Hualin Ma, et al.
Published: (2019-04-01)

The Long-Term Outcome of CT-Guided Pulsed Radiofrequency in the Treatment of Idiopathic Glossopharyngeal Neuralgia: A Retrospective Multi-Center Case Series
by: Jia Y, et al.
Published: (2020-08-01)

Blood Level of Tacrolimus in Patients with Severe Allergic Conjunctivitis Treated by 0.1% Tacrolimus Ophthalmic Suspension
by: Nobuyuki Ebihara, et al.
Published: (2012-01-01)